Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial.

Name: Αlpha¹ Rigor Record — Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial.
Item: Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial.
Rating: 100
Author: Αlpha¹

Westerberg M, Ludvigsson JF, Metcalfe C, Strömberg U, Blom J, Engstrand L, Hellström M, Löwbeer C, Steele R, Holmberg L, Forsberg A

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 2 high issues for “Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized controlled trial. The methods are rigorous, ethical approvals are documented, and data/code availability is exemplary. The only notable issues are minor reporting gaps (no explicit CONSORT statement) and a few copyedit-level inconsistencies in numbers.

Both reviewers classified the study as interventional (RCT), and I adopt that classification. The evaluation covered the full text, with verification components for citations, statistics, reproducibility, and preregistration. Non-applicable sub-criteria (e.g., animal housing, cell lines) were excluded. The reviewers diverged only on whether the reporting guideline was 'reported but inadequate' or 'not reported'; I synthesized as 'reported but inadequate' since the paper follows a structured format but lacks an explicit CONSORT statement.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites guidelines and prior trials (COLONPREV, NordICC) and notes the limited evidence from RCTs on primary colonoscopy and FIT versus usual care. The rationale for the study is logically derived from these gaps, and the study aims to quantify benefits and harms. Limitations of prior work are implicitly addressed by the trial's design (e.g., including a control arm).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on CRC screening and identifying gaps in evidence, particularly the lack of RCTs comparing FIT to usual care.

Evidence

paraphrase[Main, paragraph 1]

“There are several trials of colonoscopy screening, but few have examined FIT compared to usual care.”

direct quote[Main, paragraph 2]

“The aim of the present study was to assess if the randomization has resulted in the three arms being similar in terms of baseline demographic variables and medical history and to assess if the screening approaches resulted in a higher rate of diagnosis of CRC during the diagnostic phase, especially stage I–II CRC, compared to usual care.”